Valuation: MacroGenics, Inc.

Market Cap 235M 204M 190M 174M 329M 22.39B 334M 2.24B 878M 11.15B 881M 862M 37.38B P/E 2026 *
-5.5x
P/E 2027 * -2.42x
Enterprise Value 235M 204M 190M 174M 329M 22.39B 334M 2.24B 878M 11.15B 881M 862M 37.38B EV / Sales 2026 *
1.43x
EV / Sales 2027 * 2.49x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-0.27%
1 month-20.13%
3 months+19.81%
6 months+101.64%
Current year+129.19%
1 week 3.61
Extreme 3.61
4.06
1 month 3.36
Extreme 3.36
5.06
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Founder

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-2.38%-0.27%+136.54%-22.64% 235M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.35%-3.44%+44.68%+139.35% 23.41B
Weighted average by Cap. +0.23%-2.96%+28.78%+119.84%

Financials

2026 *2027 *
Net sales 164M 143M 133M 122M 231M 15.69B 234M 1.57B 615M 7.81B 617M 604M 26.2B 94.26M 81.94M 76.27M 70.02M 132M 9B 134M 899M 353M 4.48B 354M 346M 15.02B
Net income -18.31M -15.91M -14.81M -13.6M -25.68M -1.75B -26.08M -175M -68.52M -870M -68.75M -67.24M -2.92B -127M -110M -103M -94.37M -178M -12.13B -181M -1.21B -476M -6.04B -477M -467M -20.24B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
31/07/26 US$3.690 -2.38% 410,834
30/07/26 US$3.780 +3.00% 274,227
29/07/26 US$3.670 -4.68% 414,023
28/07/26 US$3.850 -3.75% 874,968
27/07/26 US$4.000 +8.11% 666,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.690USD
Average target price
6.750USD
Spread / Average Target
+82.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock